Biochemistry of Metabolism: Glycolysis, Feeder Pathways, and the Warburg Effect

Definition of the Pasteur Effect: This phenomenon describes the observation that in the absence of oxygen ( $O_2$ ), the rate of glycolysis increases significantly.
Biological Contexts: The Pasteur effect occurs during several physiological and pathological states, including: * Hypoxia (low oxygen levels). * Ischemic attacks (restriction in blood supply to tissues). * Development of some tumors.
Molecular Mechanism - Hypoxia-Inducible Factor (HIF): * The absence of oxygen triggers the activation of the transcription factor known as Hypoxia-Inducible Factor (HIF). * HIF functions to increase the expression of glycolytic enzymes within the cell.
Metabolic Consequences: * Even without oxygen, glycolysis continues to produce Adenosine Triphosphate (ATP). * To maintain this pathway, the cell must undergo fermentation to recycle the electron carrier $NAD^+$ from $NADH$ . * Energy Compensation: Because the cell cannot utilize the Tricarboxylic Acid (TCA) cycle or Oxidative Phosphorylation (OXPHOS) in the absence of $O_2$ , the overall yield of ATP per glucose molecule drops. Higher rates of glycolysis act to compensate for this lower overall ATP production efficiency.

Definition of the Warburg Effect: This effect is characterized by elevated levels of glycolysis and lactate fermentation even when sufficient oxygen ( $O_2$ ) is available to the cell.
Prevalence: It is frequently observed in cancer cells.
Genomic Origins: The Warburg effect is acquired through various mutations, including those affecting: * Glucose Transporters (GLUTs). * Glycolytic enzymes. * Hypoxia-Inducible Factor (HIF). * p53: A tumor suppressor protein. * Mitochondrial Electron Transport Chain (ETC) mutations.
Functional Advantages for Tumors: * Resource Competition: High glycolytic rates allow tumor cells to outcompete normal cells for available glucose resources. * Survival in Anoxic Microenvironments: Tumors often have internal regions with limited blood supply; by relying on glycolytic pathways, they can survive in anoxic (zero oxygen) environments. * Lactate Secretion and Acidification: The secretion of lactate creates an acidic environment that can be toxic to immune cells or cause immune cell dysregulation. Additionally, lactate can serve as a fuel source for adjacent tumor cells.

Endogenous Sources (Stored Carbohydrates): * Animals: Store glucose as Glycogen. * Plants and Fungi: Store glucose as Starch.
Dietary Sources of Carbohydrates: * Polysaccharides: Glycogen and Starch. * Disaccharides: Trehalose, Maltose, Sucrose, and Lactose. * Monosaccharides: Glucose, Fructose, Mannose, and Galactose.
Digestion and Absorption Process: * Location: Digestion begins in the mouth via the action of amylase and concludes in the intestine, primarily the small intestine. * Uptake by Intestinal Epithelium: * Glucose and Galactose: Absorbed via active transport mechanisms. * Other Sugars (e.g., Fructose): Absorbed via facilitated diffusion.

Disaccharide Breakdown: Hydrolases break down disaccharides into their constituent monosaccharides. * Trehalose: Broken down by trehalase into D-Glucose. * Lactose: Broken down by lactase into D-Galactose and D-Glucose. * Sucrose: Broken down by sucrase (also known as invertase) into D-Fructose and D-Glucose.
Comparison of Glucose Polymer Usage: * Endogenous Glycogen/Starch (Phosphorolysis): This process uses the enzyme glycogen phosphorylase and inorganic phosphate ( $P_i$ ) to release Glucose 1-phosphate from the nonreducing end. This conserves the energy of the glycosidic bond. * Dietary Glycogen/Starch (Hydrolysis): This process, involving enzymes like alpha-amylase, adds water ( $H_2O$ ) to break bonds, yielding free D-Glucose.

Galactose Metabolism: D-Galactose is phosphorylated by galactokinase to Galactose 1-phosphate. It is then converted into UDP-galactose, subsequently to UDP-glucose, and finally enters the glycolytic pathway as Glucose 1-phosphate.
Mannose Metabolism: D-Mannose is phosphorylated by hexokinase to Mannose 6-phosphate. The enzyme phosphomannose isomerase then converts it into Fructose 6-phosphate for glycolysis.
Glucose Metabolism: D-Glucose is converted to Glucose 6-phosphate by hexokinase (in muscle/kidney) or glucokinase (in the liver).

Tissue-Specific Pathways: Fructose enters glycolysis through two different routes depending on the tissue type: * Muscle and Kidney: Hexokinase (HK) phosphorylates fructose directly into Fructose 6-phosphate. * Liver: Fructose follows the Fructokinase (FK) and Triose Kinase pathway.
The Hepatic (Liver) Pathway: * Step 1: Fructose is converted to Fructose 1-phosphate by Fructokinase (FK). * Step 2: Fructose 1-phosphate is split by Fructose 1-phosphate aldolase into Dihydroxyacetone phosphate (DHAP) and Glyceraldehyde. * Step 3: Glyceraldehyde is phosphorylated by triose kinase using ATP to become Glyceraldehyde 3-phosphate ( $G3P$ ). * Step 4: DHAP and G3P enter the standard glycolysis pathway.
Fructose Transport Proteins: * GLUT5: Responsible for fructose transport in the intestine. * GLUT2: Responsible for transport in the liver and pancreas.
Clinical and Nutritional Implications: * High Fructose Corn Syrup (HFCS-55): Composed of $55\%$ fructose and $42\%$ glucose. Fructose is metabolically distinct from glucose. * Liver Processing: Approximately $60-70\%$ of fructose in the blood is metabolized by the liver via Fructokinase. * Bypassing Regulation: Fructose metabolism in the liver bypasses Phosphofructokinase-1 (PFK1), which is the primary rate-limiting and regulatory step of glycolysis. * Lipogenesis: Because it bypasses PFK1, the liver predominantly converts fructose into lipids.

Gut Metabolism: Fructose metabolism begins in the gut, where $80-90\%$ is broken down by the gut microbiota and intestinal cells.
Systemic Effects: Leftover fructose and its microbial metabolites (such as acetate) enter the bloodstream and travel to the liver.
De Novo Lipogenesis (DNL): * Hepatic Fructose 1-phosphate (F1P) and microbial acetate promote DNL. * This process involves metabolic and regulatory effects that bypass traditional checkpoints. * Key Bypass Points: The pathway utilizes Khk (fructokinase) and ACLY (ATP citrate lyase), effectively bypassing the PFK1 regulatory step of glycolysis.